In the last trading session, 1.45 million shares of the Arcus Biosciences Inc (NYSE:RCUS) were traded, and its beta was 0.85. Most recently the company’s share price was $7.68, and it changed around -$0.5 or -6.11% from the last close, which brings the market valuation of the company to $812.85M. RCUS currently trades at a discount to its 52-week high of $18.98, offering almost -147.14% off that amount. The share price’s 52-week low was $6.50, which indicates that the current value has risen by an impressive 15.36% since then. We note from Arcus Biosciences Inc’s average daily trading volume that its 10-day average is 1.43 million shares, with the 3-month average coming to 1.06 million.
Arcus Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.38. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended RCUS as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Arcus Biosciences Inc is expected to report earnings per share of -1.01 for the current quarter.
Arcus Biosciences Inc (NYSE:RCUS) trade information
Instantly RCUS has showed a red trend with a performance of -6.11% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 8.36 on recent trading dayincreased the stock’s daily price by 8.13%. The company’s shares are currently down -48.42% year-to-date, but still up 5.79% over the last five days. On the other hand, Arcus Biosciences Inc (NYSE:RCUS) is -17.77% down in the 30-day period. We can see from the shorts that 8.45 million shares have been sold at a short interest cover period of 8.71 day(s).
The consensus price target as assigned by Wall Street analysts is $33, which translates to bulls needing to increase their stock price by 76.73% from its current value. Analyst projections state that RCUS is forecast to be at a low of $20 and a high of $46.
Arcus Biosciences Inc (RCUS) estimates and forecasts
The year-over-year growth rate is expected to be -40.16%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 38.41M in revenue for the current quarter. 7 analysts expect Arcus Biosciences Inc to make 36.98M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 145M and 39M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -73.51%. Forecasts for the next quarter put sales growth at -5.18%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -10.20%. Arcus Biosciences Inc earnings are expected to increase by -33.47% in 2025, but the outlook is negative -7.23% per year for the next five years.
RCUS Dividends
Arcus Biosciences Inc’s next quarterly earnings report is expected to be released on 2025-Feb-24.
Arcus Biosciences Inc (NYSE:RCUS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.52% of Arcus Biosciences Inc shares, and 83.69% of them are in the hands of institutional investors. The stock currently has a share float of 88.57%. Arcus Biosciences Inc stock is held by 269.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 11.3261% of the shares, which is about 9.76 million shares worth $148.69 million.
VANGUARD GROUP INC, with 6.099% or 5.26 million shares worth $80.07 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 4.24 shares worth $32.55 million, making up 4.03% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 1.58 shares worth around $12.16 million, which represents about 1.51% of the total shares outstanding.
